Related Experiment Videos

Polymyalgia rheumatica and giant cell arteritis

J M Evans1, G G Hunder

  • 1Section of Geriatrics, Mayo Clinic, Rochester, Minnesota, USA.

Insights

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are linked inflammatory conditions. While corticosteroids are standard treatment, new markers like IL-6 offer better disease activity insights.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are common, related inflammatory conditions.
  • These diseases are increasingly understood to involve a cellular inflammatory response, potentially triggered by infections in genetically susceptible individuals.
  • Giant cell arteritis (GCA) is now recognized to frequently involve the proximal aorta, not just branch vessels.

Purpose of the Study:

  • To summarize the current understanding of PMR and GCA.
  • To highlight advancements in understanding the pathophysiology and scope of GCA.
  • To discuss current and potential future markers for disease activity.

Main Methods:

  • Review of existing literature on PMR and GCA.
  • Analysis of current evidence regarding disease mechanisms and presentation.
  • Evaluation of diagnostic and monitoring tools.

Main Results:

  • PMR and GCA represent a disease continuum with excellent prognosis despite potential complications.
  • Corticosteroids are the primary treatment but are not curative.
  • Erythrocyte sedimentation rate (ESR) is a useful marker, but C-reactive protein (CRP) and Interleukin-6 (IL-6) may offer more precise disease activity information.

Conclusions:

  • PMR and GCA are significant rheumatologic conditions requiring ongoing management.
  • Understanding the expanded vascular involvement in GCA is crucial for patient care.
  • Further research into inflammatory markers like IL-6 could improve treatment monitoring for these conditions.

Related Concept Videos